HeraMED Limited (ASX:HMD) Secures US$317,200 Lee Health Contract and Starts Epic Integration

Sonal Goyal

30 October 2026 05:27 PM AEDT

HeraMED Limited (ASX:HMD) Secures US$317,200 Lee Health Contract and Starts Epic Integration

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Lee Health moved from pilot to paid commercial deployment of HeraMED's Digital Pregnancy Journey.
An initial Statement of Work worth US$317,200 (A$453,142) covers the first 200 mothers and was paid in early October 2026.
Epic EMR integration has started, with completion targeted for March 2027.
Cash was A$2.13m at 30 September 2026, or about A$2.58m pro forma after the Lee Health receipt.

HeraMED Limited (ASX:HMD) has released its quarterly activities report and Appendix 4C for the September 2026 quarter. The medical data and technology company, which focuses on women's and maternity care, reported its first paid commercial deployment with a major US health system.

Lee Health Commercial Deployment

Lee Health, a US health system delivering more than 8,000 babies each year, began full commercial deployment of HeraMED's Digital Pregnancy Journey on 15 September 2026 after a six-month pilot. The pilot recorded 92% virtual adoption, a 100% likelihood to recommend and a Net Promoter Score of 60 for the program.

The model delivers prenatal care through an 11-visit digital-first pathway, compared with about 15 in-person visits under the traditional approach. The initial Statement of Work of US$317,200 covers the first 200 mothers and includes 12-month HeraCARE licences, monitoring kits, customised care pathways, implementation and Epic integration. Lee Health can order further cohorts in increments of 20, 50, 100 or more, and a second clinic at Fort Myers has been onboarded.

Partnerships and US Pipeline

HeraMED said an expanded commercial agreement with Philips is nearing finalisation, building on a foundation agreement signed in November 2025. The two companies continue joint US engagement and deployment planning.

The company is also progressing pilot discussions with other major US health systems and is pursuing opportunities linked to the US$50 billion Rural Health Transformation Program funded by CMS. For the December quarter, HeraMED plans to focus on completing Epic integration, onboarding clinics and care teams, and starting patient enrolment at Lee Health.

Financial Position

Cash at 30 September 2026 was A$2.13m, down from A$2.927m at the previous quarter end. Including the A$453,142 Lee Health payment received in October, pro forma cash was about A$2.58m before October expenses.

Operating cash outflow for the quarter was A$791k, including A$417k in administration and corporate costs and A$185k in research and development. The company has no loan facilities, and the Appendix 4C estimates about 2.7 quarters of funding.

Key Takeaways

Lee Health is HeraMED's first paid commercial deployment with a major US health system.
Pilot results showed high patient adoption and satisfaction.
An expanded Philips agreement and further US health system discussions are in progress.
Pro forma cash of about A$2.58m provides an estimated runway of under three quarters.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.